EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
馬薩諸塞州沃特敦，2024年12月16日（GLOBE NEWSWIRE）-- EyePoint Pharmaceuticals, Inc.（納斯達克代碼：EYPT）是一家致力於開發和商業化治療方案，以改善患有嚴重視網膜疾病的患者生活質量的公司，今天宣佈公司根據納斯達克上市規則5635(c)(4)，向新員工授予了非法定股票期權作爲誘導獎勵，超出了公司2023年長期激勵計劃的範圍。
The Company granted stock options to purchase up to an aggregate of 54,600 shares of EyePoint Pharmaceuticals common stock to six new employees. The stock options were granted on December 13, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.46 per share, the closing price of EyePoint Pharmaceuticals' common stock on December 13, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.
該公司向六名新員工授予了購買EyePoint Pharmaceuticals普通股的期權，總額可達54,600股。這些期權於2024年12月13日授予。授予經過薪酬委員會的批准，並作爲每位員工進入EyePoint Pharmaceuticals工作的誘因，符合納斯達克上市規則5635(c)(4)。期權獎勵的行使價格爲每股7.46美元，即EyePoint Pharmaceuticals普通股在2024年12月13日的收盤價。這些期權的期限爲十年，並在四年內逐步解鎖，其中25%的原始股份數量將在相關員工授予日期的第一週年時解鎖，其餘部分將在接下來的三年內按月均等解鎖。期權的解鎖取決於員工在相關解鎖日期之前繼續在EyePoint Pharmaceuticals服務。
About EyePoint Pharmaceuticals
關於eyepoint pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.
EyePoint Pharmaceuticals（納斯達克：EYPT）是一家臨床階段的生物製藥公司，致力於開發和商業化創新療法，以改善嚴重視網膜疾病患者的生活。該公司的產品線利用其專有的生物可降解Durasert E技術進行持續的眼內藥物輸送。該公司的主要產品候選藥物DURAVYU（前稱EYP-1901）是一種研究中的持續輸送治療，用於VEGF介導的視網膜疾病，結合了vorolanib，一種具有專利保護的選擇性酪氨酸激酶抑制劑及生物可降解Durasert E。DURAVYU目前正在進行Phase 3全球關鍵臨床試驗，作爲溼性AMD的持續輸送治療，該病是美國50歲及以上人群中導致視力喪失的主要原因，並且正在進行Phase 2臨床試驗以治療DME。EyePoint預計將在2025年第一季度獲得DME Phase 2臨床試驗的完整數據，以及在2026年獲得溼性AMD兩個Phase 3關鍵試驗的頂線數據。
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The proven Durasert drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
開發項目包括EYP-2301，一種TIE-2激動劑，razuprotafib，採用Durasert E配方，旨在改善嚴重視網膜疾病的治療效果。經過驗證的Durasert藥物輸送技術已安全應用於數千名患者的眼睛，涵蓋四種獲得美國FDA批准的產品。EyePoint Pharmaceuticals總部位於馬薩諸塞州的沃特鎮。
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
Vorolanib由Betta Pharmaceuticals的子公司Equinox Sciences獨家授權給EyePoint，用於中國、澳門、香港和臺灣以外的所有眼部疾病的局部治療。
DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
DURAVYU已被FDA有條件接收爲EYP-1901的專有名稱。DURAVYU是一種臨床產品；尚未獲得FDA批准。FDA的批准及潛在批准的時間表仍不確定。
For EyePoint Pharmaceuticals:
對於EyePoint Pharmaceuticals：
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
投資者：
克里斯蒂娜·塔爾塔利亞
精準AQ（原名斯特恩IR）
直撥電話：212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
媒體聯繫人：
艾米·菲利普斯
綠色房間通信-半導體
直線電話：412-327-9499
aphillips@greenroompr.com
譯文內容由第三人軟體翻譯。
